Marcia S Brose

Marcia S Brose

UNVERIFIED PROFILE

Are you Marcia S Brose?   Register this Author

Register author
Marcia S Brose

Marcia S Brose

Publications by authors named "Marcia S Brose"

Are you Marcia S Brose?   Register this Author

60Publications

1542Reads

16Profile Views

Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer.

Eur J Cancer 2019 Jan 22;106:61-68. Epub 2018 Nov 22.

Los Angeles Biomedical Research Institute and Division of Endocrinology and Metabolism, Harbor-UCLA Medical Center, Torrance, CA, USA; David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2018.10.002DOI Listing
January 2019

Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT).

Cancer 2018 06 14;124(11):2365-2372. Epub 2018 Apr 14.

Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy and University Paris-Saclay, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31344DOI Listing
June 2018

Management of treatment-related toxicities in advanced medullary thyroid cancer.

Cancer Treat Rev 2018 May 22;66:64-73. Epub 2018 Apr 22.

Dana-Farber Cancer Institute, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2018.04.007DOI Listing
May 2018

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.

N Engl J Med 2018 02;378(8):731-739

From Memorial Sloan Kettering Cancer Center (A. Drilon, J.F.H., R.B., M.L., D.M.H.) and Weill Cornell Medical College (A. Drilon, D.M.H.), New York; University of Texas Southwestern Medical Center-Children's Health, Dallas (T.W.L.); Stanford Cancer Center, Stanford University, Palo Alto (S.K.), Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California (L.M.), and UCLA David Geffen School of Medicine (N.F.), Los Angeles, and Loxo Oncology, South San Francisco (B.B.T., K.E., S.C., N.C.K., M.C.C.) - all in California; Dana-Farber-Boston Children's Cancer and Blood Disorders Center (S.G.D.), Dana-Farber Cancer Institute (G.D.D., M.N.), Ludwig Center at Harvard (G.D.D.), and Massachusetts General Hospital (A.F.F.) - all in Boston; the Finsen Center, Rigshospitalet, Copenhagen (U.N.L.); University of Colorado, Aurora (R.C.D.); St. Jude Children's Research Hospital, Memphis (A.S.P.), and Vanderbilt University, Nashville (J.B.) - both in Tennessee; Cincinnati Children's Hospital Medical Center, Cincinnati (B.T.); University Hospitals of Cleveland Medical Center (A. Dowlati) and Taussig Cancer Institute, Cleveland Clinic (D.P.S.S.), Cleveland; University of Pennsylvania Perelman School of Medicine, Department of Otorhinolaryngology and Head and Neck Surgery, and the Abramson Cancer Center (M.S.B.), and Fox Chase Cancer Center (W.S.E.-D.), Philadelphia; University of Washington-Seattle Cancer Care Alliance (C.B.), Seattle Children's Hospital (E.R.R.), and Seattle Children's Hospital, University of Washington, Fred Hutchinson Cancer Research Center (D.S. Hawkins), Seattle; University of Texas M.D. Anderson Cancer Center, Houston (F.M.-B., D.S. Hong); Inova Schar Cancer Institute, Falls Church, VA (J.D.); START Madrid, Centro Integral Oncológico Clara Campal, Madrid (V.B.); Nemours Children's Hospital, Orlando (R.N.), and Memorial Cancer Institute-Florida International University, Miami (L.E.R.) - both in Florida; Oregon Health and Science University, Portland (M.T.); and WVU Cancer Institute, West Virginia University, Morgantown (P.C.M.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1714448DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5857389PMC
February 2018

Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial.

J Clin Oncol 2017 Aug 14;35(23):2692-2699. Epub 2017 Jun 14.

Marcia S. Brose, University of Pennsylvania, Philadelphia, PA; Francis P. Worden, University of Michigan Health System, Ann Arbor, MI; Kate L. Newbold, Royal Marsden Hospital, London, UK; Matthew Guo, Eisai, Woodcliff Lake, NJ; Arti Hurria, City of Hope, Duarte, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.6472DOI Listing
August 2017

Novel concepts for initiating multitargeted kinase inhibitors in radioactive iodine refractory differentiated thyroid cancer.

Best Pract Res Clin Endocrinol Metab 2017 06 12;31(3):295-305. Epub 2017 May 12.

Endocrinology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S1521690X173004
Publisher Site
http://dx.doi.org/10.1016/j.beem.2017.04.014DOI Listing
June 2017

Timing of multikinase inhibitor initiation in differentiated thyroid cancer.

Endocr Relat Cancer 2017 05 7;24(5):237-242. Epub 2017 Mar 7.

Department of Endocrine SurgeryNippon Medical School Graduate School of Medicine, Bunkyo-Ku, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/ERC-17-0016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5446590PMC
May 2017

The Challenges of Clinical Research in Rare Cancers: Bevacizumab Use in Low-Grade Serous Ovarian and Primary Peritoneal Cancers.

J Adv Pract Oncol 2017 May-Jun;8(4):388-391. Epub 2017 May 1.

Department of Otorhinolaryngology, Hospital of the University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6040873PMC
May 2017

Vemurafenib for BRAF-positive metastatic papillary thyroid cancer - Authors' response.

Lancet Oncol 2016 11;17(11):e469

Abramson Cancer Center, Department of Medicine, Haematology/Oncology, University of Pennsylvania, Stellar-Chance Laboratories, Mezzanine, 422 Curie Boulevard, Philadelphia, PA 19104, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(16)30520-4DOI Listing
November 2016

pAKT Expression and Response to Sorafenib in Differentiated Thyroid Cancer.

Horm Cancer 2016 06 18;7(3):188-95. Epub 2016 Mar 18.

Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12672-016-0253-6DOI Listing
June 2016

Sequencing of Tyrosine Kinase Inhibitors in Progressive Differentiated Thyroid Cancer.

Authors:
Marcia S Brose

Clin Adv Hematol Oncol 2016 May;14(5 Suppl 9):7-12

Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
May 2016

Best Use of the Tyrosine Kinase Inhibitors in Progressive Differentiated Thyroid Cancer: Discussion.

Clin Adv Hematol Oncol 2016 May;14(5 Suppl 9):12-3

Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
May 2016

STK11 Mutation Identified in Thyroid Carcinoma.

Endocr Pathol 2016 Mar;27(1):65-9

Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA, 19104, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007%2Fs12022-015-94
Web Search
http://link.springer.com/10.1007/s12022-015-9411-6
Publisher Site
http://dx.doi.org/10.1007/s12022-015-9411-6DOI Listing
March 2016

Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer.

Endocr Relat Cancer 2015 12;22(6):877-87

Division of Hematology/OncologyUniversity of Michigan Comprehensive Cancer Center, University of Michigan Health System, 1500 E. Medical Center Drive, Ann Arbor, Michigan 48109, USAEndocrine UnitDepartment of Medicine I, University Hospital, University of Würzburg, Würzburg, GermanyComprehensive Cancer Center MainfrankenUniversity of Würzburg, Würzburg, GermanyDepartment of Medical OncologyCancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaBeijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted DrugsBeijing, ChinaRadiotherapy DepartmentMedical University, Sofia, BulgariaInstitut BergonieBordeaux, FranceTianjin Medical University Cancer HospitalTianjin, ChinaFondazione IRCCS Ca' GrandaMilan, ItalyDepartment of Pathophysiology and TransplantationUniversity of Milan, Milan, ItalyNagoya University HospitalNagoya, JapanAichi Cancer Center HospitalNagoya, JapanSeoul National University College of MedicineSeoul, KoreaAsan Medicine CenterSeoul, KoreaDepartment of Internal MedicineRadboud University Nijmegen Medical Center, Nijmegen, The NetherlandsBayer HealthCare PharmaceuticalsMontville, New Jersey, USABayer Pharma AGBerlin, GermanyInstitut Gustave RoussyVillejuif, FranceDepartment of Otorhinolaryngology: Head and Neck SurgeryAbramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/ERC-15-0252DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570090PMC
December 2015

The Evolving Treatment Landscape for Metastatic Differentiated Thyroid Cancer.

J Adv Pract Oncol 2014 Nov-Dec;5(6):461-5

Hospital of the University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4530117PMC
September 2015

Reply to C. Bal et al and M. Xing.

J Clin Oncol 2015 Aug 29;33(22):2483. Epub 2015 Jun 29.

Abramson Cancer Center at University of Pennsylvania, Philadelphia, PA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.61.4859DOI Listing
August 2015

Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology.

J Clin Oncol 2015 Mar 20;33(7):786-809. Epub 2015 Jan 20.

Gregory Masters, Helen F. Graham Cancer Center, Newark, DE; Lada Krilov and Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Howard H. Bailey, University of Wisconsin Hospital and Clinics, Madison, WI; Marcia S. Brose, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Harold Burstein and Lisa R. Diller, Dana-Farber Cancer Institute; Don S. Dizon, Massachusetts General Hospital, Boston, MA; Howard A. Fine, New York University Langone Medical Center; Gary K. Schwartz, Columbia University Medical Center, New York, NY; Gregory P. Kalemkerian, University of Michigan Health System; Sandra L. Wong, University of Michigan, Ann Arbor, MI; Mark Moasser, University of California San Francisco School of Medicine; Charles J. Ryan and Alan P. Venook, University of California San Francisco, San Francisco; Steven J. O'Day, Beverly Hills Health Center, Beverly Hills, CA; Michael N. Neuss, Vanderbilt-Ingram Cancer Center, Nashville, TN; Olatoyosi Odenike, University of Chicago; and Jyoti D. Patel, Northwestern University, Chicago, IL.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2015/01/16/JCO.2014.59
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.59.9746
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.59.9746DOI Listing
March 2015

BRAF mutation and thyroid cancer recurrence.

J Clin Oncol 2015 Jan 24;33(1):7-8. Epub 2014 Nov 24.

Abramson Cancer Center at University of Pennsylvania, Philadelphia, PA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.59.3657DOI Listing
January 2015

Sorafenib for patients with differentiated thyroid cancer--authors' reply.

Lancet 2015 Jan;385(9964):228-9

Bayer Pharma AG, Berlin, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(15)60056-3DOI Listing
January 2015

A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer.

Thyroid 2014 Oct 27;24(10):1508-14. Epub 2014 Aug 27.

1 Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas M.D. Anderson Cancer Center , Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/thy.2014.0125DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4195402PMC
October 2014

Second-line treatment for advanced thyroid cancer: an indication in need of randomized clinical trials.

J Clin Endocrinol Metab 2014 Jun;99(6):1995-7

Department of Medicine (A.B.C., M.S.B.) and Department of Otorhinolaryngology, Head and Neck Surgery (M.S.B.), Abramson Cancer Center at University of Pennsylvania, Philadelphia, Pennsylvania 19104.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/jc.2014-2236DOI Listing
June 2014

Management of sorafenib-related adverse events: a clinician's perspective.

Semin Oncol 2014 Feb 9;41 Suppl 2:S1-S16. Epub 2014 Jan 9.

Assistant Professor of Medicine, Department of Medical Oncology, Yale School of Medicine, New Haven, CT.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2014.01.001DOI Listing
February 2014

Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.

J Clin Oncol 2014 Jan 10;32(2):129-60. Epub 2013 Dec 10.

Jyoti D. Patel, Northwestern University; Blasé Polite, University of Chicago Medicine, Chicago, IL; Lada Krilov, American Society of Clinical Oncology, Alexandria, VA; Sylvia Adams and William L. Carroll, New York University Cancer Institute; Carol Aghajanian, Mark G. Kris, and Gary K. Schwartz, Memorial Sloan-Kettering Cancer Center, New York, NY; Ethan Basch, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Marcia S. Brose, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Marcos de Lima and Mark R. Gilbert, University of Texas MD Anderson Cancer Center, Houston; Ian Thompson, University of Texas Health Science Center at San Antonio, San Antonio, TX; John L. Marshall, Lombardi Cancer Center, Washington, DC; Gregory A. Masters, Helen F. Graham Cancer Center, Newark, DE; Steven J. O'Day, Beverly Hills Health Center, Beverly Hills, CA; Sunil Sharma, Huntsman Cancer Institute, Salt Lake City, UT; Nicholas J. Vogelzang, US Oncology Research, Comprehensive Cancer Centers of Nevada, Henderson, NV; and Bruce J. Roth, Washington University in St Louis, St Louis, MO.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.53.7076DOI Listing
January 2014

Cabozantinib in progressive medullary thyroid cancer.

J Clin Oncol 2013 Oct 3;31(29):3639-46. Epub 2013 Sep 3.

Rossella Elisei, University of Pisa, Pisa; Lisa Licitra, Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico-Istituto Nazionale dei Tumori, Milan, Italy; Martin J. Schlumberger, Institut Gustave Roussy, University Paris-Sud, Villejuif, France; Stefan P. Müller, Universitatsklinikum Essen, Essen; Michael C. Kreissl, Universitätsklinikum Würzburg, Würzburg, Germany; Patrick Schöffski, University Hospitals Leuven, Leuven, Belgium; Marcia S. Brose, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Manisha H. Shah, Ohio State University Medical Center, Columbus, OH; Barbara Jarzab, Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie Oddział w Gliwicach, Gliwice, Poland; Viktor Medvedev, Medical Radiological Research Centre of the Russian Academy of Medical Sciences, Obninsk, Russia; Bruno Niederle, Medizinische Universität Wien, Wien, Austria; Ezra E.W. Cohen, University of Chicago, Chicago, IL; Lori J. Wirth, Massachusetts General Hospital, Boston, MA; Haythem Ali, Henry Ford Health System, Detroit, MI; Colin Hessel and Yifah Yaron, Exelixis, South San Francisco, CA; Douglas Ball and Barry Nelkin, Johns Hopkins University School of Medicine, Baltimore, MD; and Steven I. Sherman, University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.48.4659DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164813PMC
October 2013

Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study.

J Am Acad Dermatol 2012 Dec 18;67(6):1265-72. Epub 2012 May 18.

Department of Dermatology, Hospital of University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2012.04.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4838029PMC
December 2012

Regional approaches to the management of patients with advanced, radioactive iodine-refractory differentiated thyroid carcinoma.

Expert Rev Anticancer Ther 2012 Sep;12(9):1137-47

Abramson Cancer Center, Department of Otorhinolaryngology: Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA 19104, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/era.12.96DOI Listing
September 2012

RAP1GAP inhibits cytoskeletal remodeling and motility in thyroid cancer cells.

Endocr Relat Cancer 2012 Aug 22;19(4):575-88. Epub 2012 Jul 22.

Department of Pharmacology - Head and Neck Surgery, School of Medicine, University of Pennsylvania, 421 Curie Boulevard, BRB II/III, Philadelphia, PA 19104, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/ERC-12-0086DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3531979PMC
August 2012

In search of a real "targeted" therapy for thyroid cancer.

Authors:
Marcia S Brose

Clin Cancer Res 2012 Apr 26;18(7):1827-9. Epub 2012 Mar 26.

Departments of Medicine and Otorhinolaryngology: Head and Neck Surgery, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19010, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-12-0153DOI Listing
April 2012

Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas.

Neuro Oncol 2010 Jul 14;12(7):621-30. Epub 2010 Feb 14.

The Children's Hospital of Philadelphia, Room 1002 Abramson Research Building, 3615 Civic Center Boulevard, Philadelphia, PA 19104, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noq007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2940652PMC
July 2010

Downregulation of Rap1GAP in human tumor cells alters cell/matrix and cell/cell adhesion.

Mol Cell Biol 2010 Jul 3;30(13):3262-74. Epub 2010 May 3.

Department of Pharmacology, University of Pennsylvania School of Medicine, 421 Curie Blvd., BRB II/III, Philadelphia, PA 19104-6061, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1128/MCB.01345-09DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2897574PMC
July 2010

Targeting vascular endothelial growth factor receptor in thyroid cancer: the intracellular and extracellular implications.

Clin Cancer Res 2010 Feb 26;16(3):778-83. Epub 2010 Jan 26.

Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-08-2743DOI Listing
February 2010

Sorafenib-Related Hand-Foot Skin Reaction Improves, Not Worsens, with Continued Treatment.

Clin Cancer Res 2009 Dec;15(24):7749

Abramson Cancer Center of the University of Pennsylvania Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-09-1190DOI Listing
December 2009

Thyroid cancer update: dramatic changes in the treatment of a rare disease.

Authors:
Marcia S Brose

Oncology (Williston Park) 2009 Aug;23(9):778, 781

Abramson Cancer Center, Department of Otorhinolaryngology, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, USA.

View Article

Download full-text PDF

Source
August 2009

Loss of Rap1GAP in papillary thyroid cancer.

J Clin Endocrinol Metab 2009 Mar 9;94(3):1026-32. Epub 2008 Dec 9.

Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/jc.2008-1042DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2681278PMC
March 2009

Phase II trial of sorafenib in advanced thyroid cancer.

J Clin Oncol 2008 Oct 9;26(29):4714-9. Epub 2008 Jun 9.

Developmental TherapeuticsProgram of the Abramson CancerCenter, University of Pennsylvania,Philadelphia, PA 19104, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2008.16.3279DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2653134PMC
October 2008

Downregulation of Rap1GAP contributes to Ras transformation.

Mol Cell Biol 2007 Oct 23;27(19):6647-58. Epub 2007 Jul 23.

Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104-6061, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1128/MCB.00155-07DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2099240PMC
October 2007

Genome-wide profiling of oral squamous cell carcinoma by array-based comparative genomic hybridization.

Laryngoscope 2006 May;116(5):735-41

Department of Otorhinolaryngology, Head and Neck, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.mlg.0000205141.54471.7fDOI Listing
May 2006

Her-2 targeted therapy: beyond breast cancer and trastuzumab.

Curr Oncol Rep 2006 Mar;8(2):90-5

Abramson Cancer Center of the University of Pennsylvania, 51 N. 39th Street, MAB 103, Philadelphia, PA 19104, USA.

View Article

Download full-text PDF

Source
March 2006

BRAF and RAS mutations in human lung cancer and melanoma.

Cancer Res 2002 Dec;62(23):6997-7000

Department of Medicine, Abramson Family Cancer Research Institute, University of Pennsylvania Cancer Center, Philadelphia 19104, USA.

View Article

Download full-text PDF

Source
December 2002

Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program.

J Natl Cancer Inst 2002 Sep;94(18):1365-72

Department of Medicine and Abramson Family Cancer Research Institute, University of Pennsylvania Cancer Center, Philadelphia 19104, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/94.18.1365DOI Listing
September 2002